« Previous Next » The Journal of Urology
Volume 182, Issue 6 , Pages 2670-2676 , December 2009

Effects of Denosumab on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer

Matthew R. Smith
- Massachusetts General Hospital Cancer Center, Boston, Massachusetts
- Correspondence: Massachusetts General Hospital Cancer Center, Yawkey 7038, 55 Fruit St., Boston, Massachusetts 02114 (telephone: 617-724-5257; FAX: 617-726-4899)
- Supported by a National Institutes of Health K24 Midcareer Investigator Award (5K24CA121990-02) and grants from the Prostate Cancer Foundation.
- Financial interest and/or other relationship with Amgen, GTx and Novartis.
Fred Saad
- Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada
- Financial interest and/or other relationship with Amgen and Novartis.
Blair Egerdie
- Urology Associates Urologic Medical Research, Kitchener, Ontario, Canada
- Financial interest and/or other relationship with Amgen, Astellas, Bayer HealthCare, GlaxoSmithKline and Pfizer.
Maciej Szwedowski
- Wojewódzkie Centrum Medyczne, Opole, Poland
- Financial interest and/or other relationship with Amgen.
Teuvo L.J. Tammela
- Tampere University Hospital, Tampere, Finland
- Financial interest and/or other relationship with Amgen, Orion Pharma and Ferring.
Chunlei Ke
- Amgen Inc., Thousand Oaks, California
- Financial interest and/or other relationship with Amgen.
Benjamin Z. Leder
- Endocrine Unit, Boston, Massachusetts
- Financial interest and/or other relationship with Amgen and Novartis.
Carsten Goessl
- Amgen Inc., Thousand Oaks, California
- Financial interest and/or other relationship with Amgen.

Received 21 April 2009

Forest plots of treatment effect of denosumab at 36 months in percentage change from baseline (±95% CI) in BMD at the lumbar spine. Results are presented as least squares means. Vertical bar represent

Forest plots of treatment effect of denosumab at 36 months in percentage change from baseline (±95% CI) in BMD at the lumbar spine. Results are presented as least squares means. Vertical bar represents 95% CI for percentage difference in lumbar spine BMD between denosumab and placebo for overall population at 36 months. Asterisk indicates p <0.0001 vs placebo. a indicates p <0.05 between subgroups. b indicates p <0.0001 between subgroups. NS, not significant between subgroups.
- Full-Size Image
- Download to PowerPoint
Forest plots of treatment effect of denosumab at 36 months in percentage change from baseline (±95% CI) in BMD at total hip. Results are presented as least squares means. Vertical bar represents 95% C

Forest plots of treatment effect of denosumab at 36 months in percentage change from baseline (±95% CI) in BMD at total hip. Results are presented as least squares means. Vertical bar represents 95% CI for percentage difference in total hip BMD between denosumab and placebo for overall population at 36 months. Asterisk indicates p <0.0001 vs placebo. a indicates p <0.05 between subgroups. b indicates p <0.0001 between subgroups. NS, not significant between subgroups.
- Full-Size Image
- Download to PowerPoint
Forest plots of treatment effect of denosumab at 36 months in percentage change from baseline (±95% CI) in BMD at distal 1/3 radius. Results are presented as least squares means. Vertical bar represen

Forest plots of treatment effect of denosumab at 36 months in percentage change from baseline (±95% CI) in BMD at distal 1/3 radius. Results are presented as least squares means. Vertical bar represents 95% CI for percentage difference in distal 1/3 radius BMD between denosumab and placebo for overall population at 36 months. Asterisk indicates p <0.0001 vs placebo. Dagger indicates p ≤0.01 vs placebo. a indicates p <0.05 between subgroups. NS, not significant between subgroups.
- Full-Size Image
- Download to PowerPoint